Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study

Journal of Urology

Volumn 169, Issue 6, 2003, Pages 2253-2256

  Athanasopoulos, A ^a   Gyftopoulos, K ^a   Giannitsas, K ^a   Fisfis, J ^a   Perimenis, P ^a   Barbalias, G ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Bladder; Prostatic hyperplasia; Quality of life; Urodynamics

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN; TOLTERODINE;

ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; BLADDER NECK STENOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETRUSOR DYSSYNERGIA; DRUG EFFECT; FEMALE; HUMAN; MALE; MICTURITION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; URINE RETENTION; URINE VOLUME; URODYNAMICS;

EID: 0038286511     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000067541.73285.eb     Document Type: Article

References (20)

1. Garraway, W. M., Collins, G. N. and Lee, R. J.: High prevalence of benign prostatic hypertrophy in the community. Lancet, 338: 469, 1991
2. Speakman, M. J.: Initial choices and final outcomes in lower urinary tract symptoms. Eur Urol, suppl., 40: 21, 2001
3. Jolleys, J. V., Donovan, J. L., Nachahal, K., Peters, T. J. and Abrams, P.: Urinary symptoms in the community: how bothersome are they? Br J Urol, 74: 551, 1994
4. Peters, T. J., Donovan, J. L., Kay, H. E., Abrams, P., de la Rosette, J. J. M. C. H., Porru, D. et al: The International Continence Society "Benign Prostatic Hyperplasia" study: the bothersomeness of urinary symptoms. J Urol, 157: 885, 1997
5. Rosier, P. F., de la Rosette, J. J., Wijkstra, H., Van Kerrebroeck, P. E. and Debruyne, F. M.: Is detrusor instability in elderly males related to the grade of obstruction? Neurourol Urodyn, 14: 625, 1995
6. Stoevelaar, H. J., Van De Beek, C., Casparie, A. F., McDonnel, J. and Nijs, H. G. T.: Treatment choice for benign prostatic hyperplasia: a matter of urologic preference? J Urol, 161: 133, 1999
7. Lukacs, B., Comet, D., Grange, J. C. and Thibault, P.: Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice. Br J Urol, 80: 722, 1997
8. Schafer, W., Waterbär, F., Langen, P.-H. and Deutz, F.-G.: A simplified graphical procedure for detailed analysis of detrusor and outlet function during voiding. Neurourol Urodyn, 8: 405, 1989
9. Abrams, P., Feneley, R. and Torrens, M.: Urodynamic investigations. In: Urodynamics. Berlin: Springer-Verlag, pp. 28-95, 1983
10. Schulman, C. C.: Long-term aspects of medical treatment of BPH. Eur Urol, suppl., 40: 8, 2001
11. Chapple, C. R. and Smith, D.: The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br J Urol, 73: 117, 1994
12. Madersbacher, S., Klingler, H. C., Schatzl, G., Stulnig, T., Schmidbauer, C. P. and Marberger, M.: Age related urodynamic changes in patients with benign prostatic hyperplasia. J Urol, 156: 1662, 1996
13. Perlberg, S. and Caine, M.: Adrenergic response of bladder muscle in prostatic obstruction. Its relation to detrusor instability. Urology, 20: 524, 1982
14. Price, D.: Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists. Eur Urol, suppl., 40: 5, 2001
15. McNeill, S. A., Hargreave, T. B., Geffriaud-Ricouard, C., Santoni, J. and Roehrborn, C. G.: Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. Urology, 57: 459, 2001
16. Lee, M.: Tamsulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother, 34: 188, 2000
17. Dunn, C. J., Matheson, A. and Faulds, D. M.: Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging, 19: 135, 2002
18. Scarpa, R. M.: Lower urinary tract symptoms: what are the implications for the patients? Eur Urol, suppl., 40: 12, 2001
19. Schulmann, C. C., Cortvriend, J., Jonas, U., Lock, T. M., Vaage, S. and Speakman, M. J.: Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur Urol, 36: 609, 1999
20. Narayan, P. and Lepor, H.: Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology, 57: 466, 2001